<< Back
Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing

Management Joined by Leading Scientists and Clinicians to Discuss Study Results and Other Business Updates

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Sept. 23, 2008--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic-analysis and molecular diagnostic solutions, announced additional, positive results from screening studies using the Company's noninvasive circulating cell-free fetal (ccff) nucleic acid SEQureDx(TM) Technology, which enables the detection of fetal aneuploidy, including Down syndrome from maternal blood, at its Analyst Briefing in New York City. Among the data presented, Sequenom's test demonstrated complete concordance with clinical results (no false positives and no false negatives) in both first and second trimester samples (over 200 samples announced today and in excess of 400 prospective samples to-date). Sequenom executives were joined by a panel of leading scientists and clinicians to discuss these study results and updates in the development of noninvasive prenatal diagnostics.

"These data expand upon the data we announced in June and underscore the potential for our SEQureDx Technology to transform current clinical practice for prenatal diagnostics as a primary screening tool for Trisomy 21. Furthermore, these results support the potential for our test to be used in the first trimester," said Harry Stylli, Ph.D., Sequenom's President and Chief Executive Officer. "In addition, our announcement earlier today regarding our acquisition of the Center for Molecular Medicine, a CLIA-certified molecular diagnostics laboratory, and our partnership with Spectrum Health and the Van Andel Research Institute, provides us with important infrastructure and commercialization control. We are delighted with our progress in bringing to market an important, noninvasive screening test for Down syndrome, as well as a broader menu of molecular diagnostic tests. These results are very promising, and we look forward to continuing the clinical development and validation progress to launch in the first half of 2009."

Elizabeth Dragon, Ph.D., Senior Vice President of Research and Development at Sequenom, presented data from blinded studies performed at Sequenom involving 219 new clinical samples collected prospectively, showing that its proprietary test for Down syndrome correctly identified 100% of all Down syndrome samples (i.e. sensitivity or detection rate), without any false-positive outcomes (i.e. specificity). The SEQureDx prototype test also demonstrated its ability to correctly identify a Down syndrome positive sample in the first trimester, confirmed by chorionic villus sampling (CVS), a current testing standard that requires the harvesting of placental tissue cells.

Sequenom indicated that with the addition of new SNPs in PLAC4 and a recently discovered gene, the SEQureDx Trisomy 21 test should increase its coverage from 93% to greater than 95% in the US population. The Company has also identified novel markers for Trisomy 18 that have passed its initial selection criteria, and other chromosomes, and intends to develop these markers into new tests.

The Company expects to continue its current development activities through the end of 2008, at which time the Company will initiate a multi-site 3,000 to 5,000-sample laboratory developed test (LDT) validation study, which is expected to be completed and submitted for publication at the time of the anticipated commercial launch in June 2009. To facilitate the LDT validation study, Sequenom also indicated that the company will be collaborating with new clinical partners who perform in excess of 12,000 amniocenteses and 3,000 CVS per year. In addition, Sequenom announced sponsorship of the RNA Noninvasive Aneuploidies ("RNA") study, a landmark, multi-center, prospective study involving up to 10,000 samples from first and second trimester pregnancies using the SEQureDx technology, managed and analyzed by an independent third-party.

During the Analyst Briefing, management also highlighted key upcoming milestones for the prenatal diagnostics business, including:

    --  Confirm 10-week or earlier gestational age testing

    --  Evaluate integration of T18 (Edward's syndrome) assay into the
        first generation test

    --  Initiate T21 LDT clinical validation study evaluating 3,000 to
        5,000 samples

    --  Complete T21 testing of up to 800 additional high prevalence
        specimens by year-end 2008

    --  Initiate "RNA" multi-center study involving 10,000 high
        prevalence patient samples

    --  Submission of key data for publication

    --  Commercial launch of T21 test in first half of 2009

Sequenom's analyst briefing included the following speakers and topics:

    --  Harry Stylli, Ph.D., Chief Executive Officer, Sequenom
        Business Overview and Update

    --  Charles R. Cantor, Ph.D., Chief Scientific Officer, New
        applications of the Sequenom Platform

    --  Yury Khudyakov, Ph.D., Chief, Molecular Epidemiology and
        Bioinformatics Laboratory, Division of Viral Hepatitis,
        Centers for Disease Control and Prevention, Novel Molecular
        Technologies for Public Health

    --  Betty Dragon, Ph.D., Senior Vice President, R&D, Noninvasive
        Prenatal Detection of Genetic Abnormalities Using SEQure
        Dx(TM) Technology

    --  Daniel H. Farkas, PhD, HCLD, FACB, Executive Director, Center
        for Molecular Medicine, Real-world Genetic Testing:
        Translating Science Into Routine Clinical Tests

    --  Gary S. Riordan, Vice President, Regulatory Affairs and
        Quality, FDA Regulatory Environment

    --  Jacob A. Canick, Ph.D., Professor of Pathology and Laboratory
        Medicine, Brown University Medical School, Design And
        Implementation of a Landmark, Multicenter, Prospective
        Clinical Study To Validate The Safe And Accurate Detection Of
        Down Syndrome Using SEQure Dx(TM) Technology

    --  Allan T. Bombard, M.D., FACOG, FACS, FACMG, reproductive
        geneticist, Chief Medical Officer, Sharp Mary Birch Hospital,
        Are We Facing a Revolution in Noninvasive Prenatal Genetic

A recording of the webcast of the event will be available on the Company Web site at www.sequenom.com until October 7, 2008.

Sequenom's Proprietary Noninvasive Prenatal Diagnostics

Sequenom's commercial opportunities in prenatal diagnostics are built upon its SEQureDx technologies and are enabled by the pioneering inventions and associated intellectual property rights that it has exclusively licensed from Isis Innovation Ltd., the technology transfer company of the University of Oxford, as well as The Chinese University of Hong Kong. Sequenom's portfolio of noninvasive prenatal diagnostic patent rights and patent applications is platform-independent, includes genetic-analysis methods using circulating cell-free fetal nucleic acids from maternal serum, plasma or whole blood, and also includes a portfolio of methylation and nucleic-acid markers. Sequenom holds exclusive rights in territories including the United States, Europe, Australia, Canada, Japan and Hong Kong. Sequenom is actively expanding its intellectual property position with new technology and new territories. Because Sequenom's license rights are platform-independent, the rights provide exclusivity (with the narrow exception in Europe for RT-PCR-based Rhesus D tests) for development and commercialization of noninvasive prenatal screens and tests on any platform and are not limited to the Company's MassARRAY platform.

About SEQureDx Technology

Sequenom's SEQureDx Technology is a novel approach to genetic screening. Unlike current standards of harvesting placental tissue cells as is required for chorionic villus, or entering the uterus to sample the amniotic fluid surrounding the baby as is performed with amniocentesis, SEQureDx Technology extracts Fetal Nucleic Acid material safely and comfortably from a simple blood specimen collected from the mother to determine the genetic status of the fetus. This breakthrough suggests that effective screening may be accomplished in the future without the risks associated with disturbing the amniotic fluid that surrounds the baby in the uterus. In December 2007, the Company, through its laboratory partner, introduced a laboratory-developed RHD genotyping test using RT-PCR in the United States. In February 2008, Sequenom announced progress with its noninvasive Trisomy 21 test based on multiple RNA fetal markers, including the PLAC4 gene as previously published by Dr. Dennis Lo, Chinese Hong Kong University.

About Down Syndrome

Down syndrome is a chromosomal abnormality characterized by the presence of an extra copy of genetic material on the 21st chromosome, either in whole (Trisomy 21) or in part (such as due to translocations). The effects of the extra copy vary greatly among people, depending on the extent of the extra copy, genetic history and pure chance. In 2007, the American College of Obstetricians and Gynecologists (ACOG) endorsed guidelines that offer risk assessment to all pregnancies for fetal chromosomal abnormalities, including Down syndrome. The ACOG recommendation includes screening before the 20th week of pregnancy using a less-invasive screening option that includes ultrasound in conjunction with the measurement of certain blood hormones. It is estimated that approximately 70%, or 2.8 million, women undergo Down syndrome screening in the United States each year.

About Sequenom

Sequenom is committed to providing the best genetic-analysis products for research and the molecular-diagnostic markets. The Company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases. Sequenom's proprietary MassARRAY system delivers reliable and specific data from complex biological samples and from genetic-target materials available only in trace amounts.

Sequenom(R), MassARRAY(R) and SEQureDx(TM) are trademarks of Sequenom, Inc.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the potential of the Company's SEQureDx Technology, the continuing development and potential of the Company's screening test for Down syndrome and other molecular diagnostic tests, the Company's acquisition of the Center for Molecular Medicine, the Company's partnership with Spectrum Health and the Van Andel Research Institute, the Company's future collaborations to conduct additional clinical testing, and the Company's sponsorship of the RNA Noninvasive Aneuploidies study are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with demand for and market acceptance of Sequenom's products, services, and technologies, new technology and product development and commercialization, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

CONTACT: Sequenom, Inc.
Paul W. Hawran
Chief Financial Officer
Investor Relations Contact
Lippert/Heilshorn & Associates
Jody Cain (jcain@lhai.com)
Kevin Mc Cabe (kmccabe@lhai.com)

SOURCE: Sequenom, Inc.
Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\84\84955\Disclaimers.xml'.